These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2148830)

  • 1. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.
    Elomaa I; Kellokumpu-Lehtinen P; Rannikko S; Alfthan O
    Eur Urol; 1991; 19(1):12-5. PubMed ID: 1706666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study.
    Anderström C; Eddeland A; Folmerz P; Hansson R; Milles S; Zachrisson B
    Eur Urol; 1995; 27(4):301-5. PubMed ID: 7656906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospective randomized multicenter phase III study of treatment of hormone refractory prostatic cancer: mitomycin C vs. 4-epirubicin vs. estramustine phosphate].
    Weissbach L
    Urologe A; 1992 Jan; 31(1):62. PubMed ID: 1553805
    [No Abstract]   [Full Text] [Related]  

  • 6. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J; Spona J
    Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 9. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
    Anderström C
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
    Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC protocols in prostatic cancer. An interim report.
    Pavone-Macaluso M; Lund F; Mulder JH; Smith PH; De Pauw M; Sylvester R
    Scand J Urol Nephrol Suppl; 1980; 55():163-8. PubMed ID: 6938020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.